Atomic Invest’s AbbVie ABBV Stock Holding History

Atomic Invest’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.9K	Sell	169 -7	-4%	-$1.51K	﹤0.01%	139
2026 Q1	$37.4K	Buy	176 +13	+8%	+$2.88K	0.02%	129
2025 Q4	$37.4K	Buy	+163	New	+$37.1K	0.02%	102

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Atomic Invest's ABBV Position: Q2 2026 in Review

Atomic Invest reduced its AbbVie (ABBV) stake by 4% in Q2 2026, selling an estimated $1.51K and leaving 169 shares worth $42.9K. The position accounts for ﹤0.01% of the portfolio, ranked #139.

Atomic Invest first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,232 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Atomic Invest held 169 shares of AbbVie worth $42.9K as of Q2 2026.
Atomic Invest sold 7 AbbVie shares in Q2 2026, an estimated $1.51K.
AbbVie made up ﹤0.01% of Atomic Invest's portfolio in Q2 2026, its #139 holding.
Atomic Invest first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,232 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Atomic Invest's 13F filing for Q2 2026, filed 25 Sep 2026.